Zhi-Bo Gu

Apr 3, 2024 | dovepress.com | Lei Qiu |Hua Zhu |Ming Lu |Zhi-Bo Gu

Introduction The prevalence of lower urinary tract symptoms attributed to benign prostatic hyperplasia (LUTS/BPH) is on the rise, particularly within the aging demographic.1 This cohort of patients often presents with concomitant cardiovascular diseases, necessitating ongoing antiplatelet (AP) therapy.2 Continuous administration of AP agents has demonstrated efficacy in reducing the incidence of cardiovascular events such as coronary heart disease, stroke, and venous thrombosis.3,4 However,...